Life (Jul 2021)

Long-Term Maintained Response to Selective Internal Radiation Therapy in an Oligometastatic Uveal Melanoma Patient Treated with Concomitant Anti-PD-1 Therapy

  • Ilaria Proietti,
  • Nevena Skroza,
  • Luca Filippi,
  • Nicoletta Bernardini,
  • Alessandra Mambrin,
  • Ersilia Tolino,
  • Giovanni Rossi,
  • Anna Marchesiello,
  • Federica Marraffa,
  • Salvatore Volpe,
  • Oreste Bagni,
  • Concetta Potenza

DOI
https://doi.org/10.3390/life11070692
Journal volume & issue
Vol. 11, no. 7
p. 692

Abstract

Read online

Uveal melanoma (UM) is a primary neoplasm of the eye arising from the melanocytes residing in the iris, ciliary body or choroid. It is the most frequent intraocular malignancy and often determines metastases at distant sites, with a peculiar tropism for the liver. Metastatic UM has a poor prognosis, as any treatment affects the natural course of this fatal disease. Herein, we report a case of a UM metastatic to the liver in a 54 year-old female patient, initially treated with nivolumab without success. The patient was then scheduled for selective internal radiation therapy (SIRT) while continuing immunotherapy. This combination led to a complete and durable response and the patient is currently free of disease, two years after the diagnosis of the hepatic metastases. The association between SIRT and immunotherapy (IT) has very promising perspectives for metastatic UM, especially considering the disappointing or contradictory results of classic chemotherapies, IT alone and targeted therapies. Furthermore, this combination has been shown to have a good security profile. However, further studies are needed to confirm the efficacy of associating SIRT and IT and to clarify some unsolved problems, such as the timing of administration of these two therapies.

Keywords